Beijing Hotgen Biotech Co Ltd (688068) - Total Assets
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) holds total assets worth CN¥3.21 Billion CNY (≈ $469.40 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Beijing Hotgen Biotech Co Ltd to assess how comfortably operating cash covers total debt obligations.
Beijing Hotgen Biotech Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See Beijing Hotgen Biotech Co Ltd (688068) shareholders funds for net asset value and shareholders' equity analysis.
Beijing Hotgen Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Hotgen Biotech Co Ltd's total assets of CN¥3.21 Billion consist of 38.9% current assets and 61.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.1% |
| Accounts Receivable | CN¥96.62 Million | 2.9% |
| Inventory | CN¥83.45 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥52.12 Million | 1.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688068 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Hotgen Biotech Co Ltd's current assets represent 38.9% of total assets in 2024, a decrease from 75.7% in 2016.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, down from 60.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Beijing Hotgen Biotech Co Ltd Competitors by Total Assets
Key competitors of Beijing Hotgen Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Beijing Hotgen Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.07 | 9.85 | 4.08 |
| Quick Ratio | 4.77 | 8.95 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.07 Billion | CN¥1.14 Billion | CN¥443.66 Million |
Beijing Hotgen Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Hotgen Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.24 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | CN¥3.33 Billion |
| Market Capitalization | $1.41 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Hotgen Biotech Co Ltd's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Beijing Hotgen Biotech Co Ltd's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual total assets of Beijing Hotgen Biotech Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.33 Billion ≈ $486.68 Million |
-6.59% |
| 2023-12-31 | CN¥3.56 Billion ≈ $521.03 Million |
-8.69% |
| 2022-12-31 | CN¥3.90 Billion ≈ $570.59 Million |
+6.98% |
| 2021-12-31 | CN¥3.64 Billion ≈ $533.36 Million |
+303.85% |
| 2020-12-31 | CN¥902.52 Million ≈ $132.07 Million |
+24.37% |
| 2019-12-31 | CN¥725.67 Million ≈ $106.19 Million |
+171.67% |
| 2018-12-31 | CN¥267.12 Million ≈ $39.09 Million |
+40.85% |
| 2017-12-31 | CN¥189.65 Million ≈ $27.75 Million |
+18.45% |
| 2016-12-31 | CN¥160.12 Million ≈ $23.43 Million |
-- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more